Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  adenocarcinoma of the rectum
Stage/Subtype:  adenocarcinoma of the rectum
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 46 for your search:
Start Over
Rectal Cancer And Pre-operative Induction Therapy Followed by Dedicated Operation. The RAPIDO Trial
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: NL36315.042.11, NCI-2014-01600, 2010-023957-12, NCT01558921
Nintedanib (BIBF 1120) vs Placebo in Refractory Colorectal Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 1199.52, NCI-2014-02486, 2012-000095-42, NCT02149108
Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 85
Trial IDs: Neogenix 0901, NCI-2012-01393, NCT01040000
Hydroxychloroquine, Fluorouracil, Leucovorin Calcium, Oxaliplatin, and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCC 07210, NCI-2010-02018, NCT01206530
Dose Finding Study of Once or Twice Weekly IMMU-130 in Metastatic Colorectal Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: IM-T-IMMU-130-02, NCI-2013-01786, NCT01605318
DNA Methyltransferase Inhibitor SGI-110 and Irinotecan Hydrochloride or Regorafenib Alone in Treating Patients with Previously Treated Metastatic Colorectal Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: NA_00085870, J1369, NCI-2013-02005, CIR00004735, CIR0002117, NA_00085870, NCT01896856
A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: INCB 24360-204, NCI-2015-00040, NCT02327078
Nintedanib and Capecitabine in Treating Patients with Refractory Metastatic Colorectal Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 265514, NCI-2015-00223, NCT02393755
PD 0332991 in Treating Patients With Refractory Solid Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCC 03909, NCI-2009-01467, NCT01037790
Yttrium Y 90 Glass Microspheres in Treating Patients With Colorectal Cancer With Liver Metastases Previously Treated With First-Line Combination Chemotherapy
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 071960, NCI-2012-03128, UCSD 071960, NCT01098422
Combination Chemotherapy with or without Regorafenib in Treating Patients with Metastatic Colorectal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: LCCC 1029, NCI-2013-00954, 10-2176, NCT01298570
Combination Chemotherapy with or without Panitumumab in Treating Patients with Colorectal Cancer with Liver Metastases Previously Treated with Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 10-137, NCI-2011-00375, NCT01312857
Gemcitabine Hydrochloride and Docetaxel in Treating Patients with Relapsed or Refractory Colorectal Cancer That Is Metastatic or Cannot Be Removed by Surgery
Phase: Phase II
Type: Treatment
Age: Over 18
Trial IDs: J1214, NCI-2012-01337, NCI-2013-01567, NCT01639131
Ziv-Aflibercept and Combination Chemotherapy in Treating Patients with Previously Untreated Colorectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU 11182, NCI-2012-01167, 2012C0055, NCT01652196
Akt Inhibitor MK2206 in Treating Patients with Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2012-0431, NCI-2013-00487, 9340, NCT01802320
Panitumumab and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Previously Treated With Combination Chemotherapy and Bevacizumab
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: OSU-11131, NCI-2013-00432, 2012C0033, NCT01814501
Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin before Surgery in Treating Patients with Stage II-III Rectal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 3R-12-2, NCI-2013-01069, 3C-12-2, HS-12-00726, ML28263, NCT01871571
Pembrolizumab in Treating Patients with Metastatic or Locally Advanced Microsatellite Unstable Solid Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: J1365, NCI-2013-02436, CIR00001187, MK-3475-016, NA_00085756, NA_00085756 / CIR00007001, NCT01876511
A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: IMMU 130-03, NCI-2014-01921, NCT01915472
Chemoradiation or Brachytherapy before Surgery in Treating Patients with Rectal Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: J1360, NCI-2014-00731, NA_00082167, NA_00082167 / CIR00008177, NCI-2014-00125, NCT02017704
Regorafenib in Treating Patients with Newly Diagnosed Metastatic Colorectal Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 13-211, NCI-2014-00002, NCT02023333
A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: RRx001-21-02, NCI-2014-00908, NCT02096354
Study of Ruxolitinib in Colorectal Cancer Patients
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: INCB18424-267, NCI-2014-01443, NCT02119676
Start Over